Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
AnaptysBio
Biotech
Anaptys picks up rival to Biogen autoimmune asset from Centessa
Anaptys is picking up a challenger to Biogen's late-phase lupus candidate, paying Centessa $7 million upfront for rights to a preclinical prospect.
Nick Paul Taylor
Nov 28, 2023 6:30am
Chasing Boehringer, Anaptys hits goal in skin disease phase 3
Oct 9, 2023 9:20am
AnaptysBio's HARP plays dud note, prompting rethink of strategy
Sep 1, 2022 8:05am
Gilead makes $405M buy to compete with Lilly's BTLA program
Aug 4, 2022 11:46am
After going 0 for 2, AnaptysBio CEO makes immediate exit
Mar 22, 2022 8:15am
AnaptysBio's ACORN fails, marking end of acne program
Mar 15, 2022 7:45am
